Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV MediciNova, Inc. daily Stock Chart
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own4.30% Shs Outstand45.76M Perf Week-8.05%
Market Cap366.08M Forward P/E- EPS next Y-0.77 Insider Trans0.00% Shs Float36.43M Perf Month-5.33%
Income-14.70M PEG- EPS next Q-0.11 Inst Own26.50% Short Float8.51% Perf Quarter-6.65%
Sales- P/S- EPS this Y-5.70% Inst Trans8.33% Short Ratio57.37 Perf Half Y-27.60%
Book/sh1.74 P/B4.60 EPS next Y-8.50% ROA-18.80% Target Price20.00 Perf Year-34.48%
Cash/sh1.36 P/C5.88 EPS next 5Y20.00% ROE-19.70% 52W Range6.68 - 14.01 Perf YTD-2.08%
Dividend- P/FCF- EPS past 5Y-12.90% ROI- 52W High-42.90% Beta1.13
Dividend %- Quick Ratio28.60 Sales past 5Y- Gross Margin- 52W Low19.76% ATR0.44
Employees9 Current Ratio28.60 Sales Q/Q- Oper. Margin- RSI (14)41.67 Volatility4.61% 3.81%
OptionableYes Debt/Eq0.00 EPS Q/Q92.20% Profit Margin- Rel Volume1.55 Prev Close8.68
ShortableYes LT Debt/Eq0.00 EarningsApr 01 AMC Payout- Avg Volume54.02K Price8.00
Recom1.50 SMA20-7.81% SMA50-9.00% SMA200-16.20% Volume83,803 Change-7.83%
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Mar-24-19 07:00PM  MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania GlobeNewswire
Mar-05-19 06:51PM  MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan GlobeNewswire
Feb-28-19 06:00PM  MediciNova Announces the Publication of Results of the Animal Model Study of MN166 (ibudilast) in Glioblastoma in Scientific Reports GlobeNewswire
Feb-20-19 10:00AM  MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS Zacks Small Cap Research
Feb-12-19 01:30PM  One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price Simply Wall St.
Jan-21-19 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases GlobeNewswire
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 06:00PM  MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma GlobeNewswire +9.13%
Jan-07-19 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan GlobeNewswire
Dec-12-18 10:06AM  Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)? Simply Wall St. +6.69%
06:00AM  MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire
Oct-31-18 10:00AM  MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy Zacks Small Cap Research +5.29%
Oct-05-18 08:35AM  The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
Oct-04-18 07:00PM  MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma GlobeNewswire
Sep-28-18 09:45AM  MNOV: Positive FDA Feedback on ALS Phase 3 Plan Zacks Small Cap Research
Sep-25-18 07:00PM  MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS GlobeNewswire
Sep-18-18 07:00PM  MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York GlobeNewswire
Sep-04-18 07:00PM  MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York GlobeNewswire
Aug-29-18 05:00PM  MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine GlobeNewswire +5.40%
Aug-20-18 07:00PM  National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder GlobeNewswire
07:50AM  Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-06-18 07:00PM  MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge GlobeNewswire
Jul-31-18 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK GlobeNewswire
Jul-29-18 07:00PM  MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial GlobeNewswire
Jul-25-18 09:15AM  MNOV: Plenty of Cash to Advance Pipeline Forward Zacks Small Cap Research
Jul-12-18 09:30AM  MNOV: Encouraging Data from Subgroup Analysis of ALS Study Zacks Small Cap Research
Jul-09-18 07:00PM  MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Jun-19-18 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan GlobeNewswire
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-31-18 07:14PM  When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable? Simply Wall St.
May-16-18 03:55PM  Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Heres How It Performed Lately Simply Wall St.
May-09-18 07:00PM  MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma GlobeNewswire
May-08-18 07:00PM  MediciNova to Present at the UBS Global Healthcare Conference in New York GlobeNewswire
May-07-18 07:00PM  MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal GlobeNewswire
May-01-18 09:20AM  MNOV: Additional Data Presented for MN-166 in MS and ALS Zacks Small Cap Research
Apr-26-18 07:00PM  MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting GlobeNewswire
Apr-24-18 06:30AM  MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data GlobeNewswire -5.05%
Apr-13-18 08:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France GlobeNewswire
Apr-12-18 08:20AM  Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-06-18 12:55PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE
Apr-02-18 04:30PM  Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today Motley Fool +18.88%
02:53PM  Here's Why MediciNova Jumped as Much as 26.2% Today Motley Fool
10:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-01-18 07:00PM  MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis GlobeNewswire
Mar-29-18 06:30AM  MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire -14.55%
Mar-28-18 07:00PM  MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy GlobeNewswire
Mar-15-18 08:15AM  Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-12-18 07:00PM  MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo GlobeNewswire
Feb-21-18 06:18PM  Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet? Simply Wall St.
Feb-18-18 06:00PM  MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Feb-16-18 10:30AM  MNOV: Raises $40 Million in Underwritten Public Offering Zacks Small Cap Research
Feb-12-18 06:30PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Feb-08-18 01:17PM  Here's Why MediciNova, Inc. Stock Is Sliding Today Motley Fool -11.41%
Feb-07-18 07:12PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire -9.49%
04:01PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
10:00AM  MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study Zacks Small Cap Research
Feb-05-18 07:00AM  Blog Exposure - MediciNovas MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial ACCESSWIRE
Feb-01-18 06:00PM  MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug GlobeNewswire +8.82%
Jan-31-18 07:00AM  MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego GlobeNewswire +6.25%
Jan-30-18 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Jan-28-18 06:00PM  MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France GlobeNewswire
Jan-16-18 06:00PM  MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan GlobeNewswire
02:04PM  What You Must Know About MediciNova Incs (NASDAQ:MNOV) Major Investors Simply Wall St.
Jan-09-18 07:13AM  Does MediciNova Incs (NASDAQ:MNOV) CEO Pay Compared Well With Peers? Simply Wall St.
Jan-01-18 05:25PM  MediciNova Inc (NASDAQ:MNOV): Whats The Analyst Consensus Outlook? Simply Wall St.
Dec-22-17 08:05PM  Does MediciNova Incs (NASDAQ:MNOV) Past Performance Indicate A Stronger Future? Simply Wall St.
Dec-13-17 11:40AM  MNOV: Positive Topline Results for MN-166 in P2 ALS Study Zacks Small Cap Research +10.02%
Dec-07-17 07:03PM  MediciNova stock up more than 50% on positive trial results MarketWatch
06:00PM  MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Nov-23-17 04:51PM  Is MediciNova Inc (MNOV) Cheap And High Growth? Simply Wall St.
Nov-10-17 01:30AM  MediciNova Appoints Hideki Nagao to its Board of Directors GlobeNewswire
Nov-09-17 06:00PM  MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder GlobeNewswire
Nov-08-17 06:59PM  Is MediciNova Inc (MNOV) Undervalued? Simply Wall St.
Nov-01-17 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA GlobeNewswire -9.99%
Oct-31-17 05:00PM  MNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MS Zacks Small Cap Research
Oct-30-17 06:00AM  MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile GlobeNewswire
Oct-26-17 06:00AM  MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability GlobeNewswire
Oct-17-17 08:05AM  MediciNova, Upcoming Phase II Data Presentation, Ibudilast Review ACCESSWIRE
Sep-19-17 06:00AM  MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire
Sep-18-17 07:00PM  MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York GlobeNewswire
Aug-30-17 06:00AM  MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France GlobeNewswire
Aug-01-17 12:00PM  MNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study Zacks Small Cap Research
Jun-05-17 04:00PM  MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois GlobeNewswire
Apr-25-17 07:00PM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston GlobeNewswire
Apr-09-17 07:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois GlobeNewswire
Feb-27-17 06:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland GlobeNewswire
12:00PM  MNOV: MN-166 Making Progress in Numerous Indications Zacks Small Cap Research
Feb-18-17 01:04PM  MEDICINOVA INC Financials
Feb-15-17 08:42AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-14-17 06:26PM  MEDICINOVA INC Files SEC form 10-K, Annual Report
Feb-07-17 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston GlobeNewswire
Feb-06-17 06:00PM  MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research GlobeNewswire
Feb-01-17 06:00PM  MediciNova to Attend Mizuho Healthcare Conference in New York GlobeNewswire
Jan-23-17 06:00PM  MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Dec-22-16 11:30AM  MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion Zacks Small Cap Research
Dec-20-16 06:00PM  MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-19-16 06:00AM  MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis GlobeNewswire
Dec-15-16 10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 Capital Cube
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Okajima MasatsuneVP and Head of Japanese OfficeFeb 28Option Exercise4.19886,9503,718,7631,040,530Mar 04 06:00 AM
Okajima MasatsuneVP and Head of Japanese OfficeJan 09Option Exercise2.2041,25090,750153,580Jan 11 04:24 PM
IWAKI YUICHIPresident and CEOJan 03Option Exercise2.2018,57240,858759,392Jan 07 06:04 AM